Developer docs
API playgroundTry for free, no card

Search company profiles

Mapi Pharma

Full company profile

uuid0002hnf

Namestring
Mapi Pharma
Legal namestring
Mapi Pharma Ltd.
Websiteurl
mapi-pharma.com
Company typeenum
Private
Founded yearint
2008
Descriptiontext

Mapi Pharma Ltd. is a privately held, clinical-stage biopharmaceutical company founded in 2008 and headquartered in Ness Ziona, Israel, with manufacturing in Jerusalem and Neot-Hovav and R&D facilities in China and Germany. The company develops proprietary long-acting depot injectable formulations — extended-release microspheres delivering drug over periods ranging from weekly to monthly — built around a platform protected by granted US patents (notably 8,377,885 B2 covering glatiramer acetate depot through December 2030) and supported by GMP-approved API and aseptic fill-finish manufacturing capacity that includes a ~50,000 sq ft former J&J/Omrix sterile injectable plant in Jerusalem.

Mapi's lead product is GA Depot (glatiramer acetate depot), a 40 mg once-monthly intramuscular injection for relapsing and primary progressive multiple sclerosis. Phase III results in 1,016 RMS patients showed a 30.1% reduction in annualized relapse rate versus placebo, the FDA accepted the NDA in August 2023, and the asset is in final regulatory review in Germany ahead of a planned 2027/2028 EU launch. Global commercialization rights for GA Depot are licensed exclusively to Viatris (formerly Mylan), which has also invested $20 million as a strategic shareholder. The broader pipeline applies the depot platform to Cariprazine Depot (schizophrenia, Phase I/II), Semaglutide and Tirzepatide Depot (metabolic/GLP-1, Phase I/II initiated 2026), Anastrozole Depot (breast cancer), Deutetrabenazine Depot (Huntington's), and Paliperidone Palmitate, with co-development partner Zhejiang Jingxin holding rights for China.

Mapi generates minimal current revenue from select-region sales of generic Naltrexone, generic Fingolimod, and generic Apremilast; the primary monetization path is licensing, manufacturing supply, and royalties tied to GA Depot's commercial launch via Viatris, supplemented by geographic distribution partners (Gaelan Medical in UAE) and the Zhejiang Jingxin product development agreement. Pricing is not publicly disclosed and the company is not yet commercial for its lead asset.

Short descriptiontext

Mapi Pharma is a privately held, clinical-stage biopharmaceutical company developing proprietary long-acting depot injectable formulations. Its lead asset, GA Depot (once-monthly glatiramer acetate), targets multiple sclerosis under an exclusive global license to Viatris, with an additional pipeline in CNS, metabolic, and oncology indications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersNess Ziona, Israel
HQ citystring
Ness Ziona
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
long-acting injectable pharmaceuticals, generic drug development, extended-release drug formulations, active pharmaceutical ingredients, aseptic fill-finish manufacturing
Industry1 code
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Long-acting injectable pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Revenue from sale of proprietary pharmaceutical products including GA Depot and generic versions of marketed drugs like Fingolimod (Gilenya) and Apremilast (Otezla) in select regions.

mapi-pharma.com
2Licensing and Partnership Revenue
TypeLicensing Royalties
Description

Revenue from strategic partnerships including manufacturing and supply agreements with Viatris for GA Depot commercialization globally, and product development agreements with partners like Zhejiang Jingxin for Chinese market.

mapi-pharma.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Mapi Pharma develops proprietary long-acting depot injectables, complex active pharmaceutical ingredients, and pharmaceutical formulations for neurological, metabolic, oncology, and other chronic conditions. It also markets selected generic drugs and operates integrated GMP-approved API and finished-dosage-form manufacturing facilities.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 30.1% reduction in annualized relapse rate (ARR) vs placebo in Phase III RMS study
+2 more records
Product overview1 text field

Mapi Pharma is a clinical-stage pharmaceutical company developing proprietary long-acting depot injectable drugs for lifecycle management of innovative and existing commercially successful pharmaceuticals. The company's lead product is GA Depot (Glatiramer Acetate Depot), a once-monthly injection for multiple sclerosis treatment partnered with Viatris and currently under FDA review. The pipeline includes multiple depot formulations across therapeutic areas: CNS disorders (Cariprazine Depot for schizophrenia, Pregabalin ER for neuropathic pain), metabolic diseases (Semaglutide Depot and Tirzepatide Depot for diabetes/weight management), and oncology (Anastrozole Depot for breast cancer). Mapi also markets generic versions of established drugs including Fingolimod (Gilenya), Apremilast (Otezla), and Naltrexone (Vivitrol). The company operates fully integrated R&D, clinical development, and GMP-approved manufacturing facilities in Israel.

Product and service13 records
1GA Depot (Glatiramer Acetate Depot)
CategoryLong-acting multiple sclerosis therapy
Description

A once-monthly 40 mg intramuscular glatiramer acetate injection for relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS), reducing administration from daily or thrice-weekly Copaxone schedules to once every four weeks.

2Semaglutide Depot
CategoryLong-acting metabolic therapy
Description

Long-acting injectable formulation of semaglutide for diabetes treatment, developed using Mapi's depot technology for once-monthly injection; currently in a Phase I/II study identified as ClinicalTrials.gov NCT07563699.

3Tirzepatide Depot
CategoryLong-acting metabolic therapy
Description

Long-acting injectable formulation of tirzepatide (Mounjaro/Zepbound) for chronic weight management, developed using Mapi's depot technology.

4Anastrozole Depot
CategoryLong-acting oncology therapy
Description

Long-acting depot formulation of anastrozole (Arimidex) for adjuvant endocrine therapy to prevent recurrence in breast cancer, supported by Mapi intellectual property and pharmacokinetic modeling.

5Cariprazine Depot
CategoryLong-acting central nervous system therapy
Description

Long-acting depot injectable for schizophrenia treatment, enrolling in a Phase I/II study with positive pharmacokinetic results supporting planned Phase III initiation in 2027.

6Deutetrabenazine Depot
CategoryLong-acting central nervous system therapy
Description

Long-acting depot injectable for Huntington's disease.

7Naltrexone Generic (Vivitrol)
CategoryMarketed generic pharmaceutical
Description

AB-rated generic version of naltrexone (Vivitrol) for opioid dependence treatment.

8Fingolimod Generic (Gilenya)
CategoryMarketed generic pharmaceutical
Description

Generic version of fingolimod marketed under the Gilenya brand for multiple sclerosis treatment and sold in select regions.

9Apremilast Generic (Otezla)
CategoryMarketed generic pharmaceutical
Description

Generic version of apremilast marketed as Apremil 30 mg for psoriasis treatment and sold in select regions.

10Pregabalin ER
CategoryExtended-release neurological therapy
Description

Extended-release formulation of pregabalin (Lyrica) for the treatment of neuropathic pain and epilepsy.

11Paliperidone Palmitate
CategoryLong-acting central nervous system therapy
Description

Long-acting depot injectable for the treatment of schizophrenia.

12Buspirone ER
CategoryExtended-release central nervous system therapy
Description

Extended-release formulation of buspirone for the treatment of schizophrenia.

13Tapentadol
CategoryPain-management pharmaceutical
Description

Pain-relief medication indicated for moderate-to-severe acute pain treatment, developed using Mapi's process for cost-effective production.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-10-21
Description

Exclusive marketing and distribution agreement for Mapi products in UAE market.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2018-04-10
Description

Mylan acquired global marketing rights to GA Depot in 2018; FDA accepted NDA filing with PDUFA target date of March 8, 2024; Mapi supplies product for commercial sale globally. Partnership strengthened with additional $20M investment in June 2020.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2016-11-05
Description

Chinese pharmaceutical company invested $10M initially in 2016 and $10M in 2018 for total $20M; product development agreement where Mapi develops products exclusively for Jingxin for Chinese market registration, manufacturing and marketing. Co-development of products for schizophrenia, diabetes, and other depot injectable indications.

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Generic and specialty injectable pharma with a broad sterile injectable portfolio. Comparable on injectable manufacturing scale, complex generics expertise, and US/EU distribution reach relevant to Mapi's planned expansion.

TypeBroad incumbent
Description

Markets Gilenya (fingolimod) for MS, a key competing oral therapy to injectable GA Depot. Comparable as a CNS specialty pharma incumbent whose franchise Mapi's pipeline and platform directly challenge.

TypeDirect peer
Description

Specialty pharma specializing in long-acting injectable depot technologies (e.g., Eligard for prostate cancer). Highly comparable on depot formulation know-how, sterile manufacturing, and urology/oncology injectable portfolio overlap.

TypeDirect peer
Description

Originator of Copaxone (daily glatiramer acetate) for MS and a fellow Israeli specialty/generic pharma. Teva is the incumbent Mapi must displace in the GA franchise, and its authorized generic makes it the closest clinical and commercial comparable.

TypeBroad incumbent
Description

Major MS player (Tysabri, Avonex, Plegridy, Vumerity) and broader neuroscience biopharma. Comparable on CNS specialty pharma franchise development, large-scale MS clinical infrastructure, and neurology-focused commercial models.

TypeBroad incumbent
Description

Global commercialization partner for GA Depot and a broader specialty/generic pharma with its own MS franchise (Copaxone authorized generic). Comparable as a large-scale neurology and complex injectable commercialization platform relevant to Mapi's go-to-market.

TypeBroad incumbent
Description

Markets Ocrevus, a leading high-efficacy MS therapy, and is expanding in progressive MS. Comparable as a broad incumbent whose MS franchise defines the competitive benchmark GA Depot must outperform in efficacy and adherence.

TypeBroad incumbent
Description

US-focused specialty and complex generic injectable manufacturer with an AffaMed and global footprint. Comparable on high-barrier generic injectables strategy and sterile manufacturing capabilities relevant to Mapi's generic and depot portfolio.

TypeEmerging player
Description

European biosimilars and complex injectables developer with MS-relevant programs (e.g., natalizumab biosimilar). Comparable as an emerging specialty injectables player targeting the same prescribers and patient pool as Mapi's GA Depot.

TypeDirect peer
Description

US specialty pharma built around long-acting injectable technology (Cinvanti, Sustol, Zynrelef). Closely comparable as a small-cap, depot/injectable-focused specialty pharma with similar capital and commercialization constraints.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mapi Pharma

Long-acting injectable pharmaceuticalsmapi-pharma.com

Mapi Pharma is a privately held, clinical-stage biopharmaceutical company developing proprietary long-acting depot injectable formulations. Its lead asset, GA Depot (once-monthly glatiramer acetate), targets multiple sclerosis under an exclusive global license to Viatris, with an additional pipeline in CNS, metabolic, and oncology indications.

What Mapi Pharma does

Mapi Pharma Ltd. is a privately held, clinical-stage biopharmaceutical company founded in 2008 and headquartered in Ness Ziona, Israel, with manufacturing in Jerusalem and Neot-Hovav and R&D facilities in China and Germany. The company develops proprietary long-acting depot injectable formulations — extended-release microspheres delivering drug over periods ranging from weekly to monthly — built around a platform protected by granted US patents (notably 8,377,885 B2 covering glatiramer acetate depot through December 2030) and supported by GMP-approved API and aseptic fill-finish manufacturing capacity that includes a ~50,000 sq ft former J&J/Omrix sterile injectable plant in Jerusalem.

Mapi's lead product is GA Depot (glatiramer acetate depot), a 40 mg once-monthly intramuscular injection for relapsing and primary progressive multiple sclerosis. Phase III results in 1,016 RMS patients showed a 30.1% reduction in annualized relapse rate versus placebo, the FDA accepted the NDA in August 2023, and the asset is in final regulatory review in Germany ahead of a planned 2027/2028 EU launch. Global commercialization rights for GA Depot are licensed exclusively to Viatris (formerly Mylan), which has also invested $20 million as a strategic shareholder. The broader pipeline applies the depot platform to Cariprazine Depot (schizophrenia, Phase I/II), Semaglutide and Tirzepatide Depot (metabolic/GLP-1, Phase I/II initiated 2026), Anastrozole Depot (breast cancer), Deutetrabenazine Depot (Huntington's), and Paliperidone Palmitate, with co-development partner Zhejiang Jingxin holding rights for China.

Mapi generates minimal current revenue from select-region sales of generic Naltrexone, generic Fingolimod, and generic Apremilast; the primary monetization path is licensing, manufacturing supply, and royalties tied to GA Depot's commercial launch via Viatris, supplemented by geographic distribution partners (Gaelan Medical in UAE) and the Zhejiang Jingxin product development agreement. Pricing is not publicly disclosed and the company is not yet commercial for its lead asset.

Mapi Pharma firmographics

Firmographics
Name
Mapi Pharma
Legal name
Mapi Pharma Ltd.
Website
https://mapi-pharma.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
51–100 employees
Short description
Mapi Pharma is a privately held, clinical-stage biopharmaceutical company developing proprietary long-acting depot injectable formulations. Its lead asset, GA Depot (once-monthly glatiramer acetate), targets multiple sclerosis under an exclusive global license to Viatris, with an additional pipeline in CNS, metabolic, and oncology indications.
Ownership category
akta.pro rank

Mapi Pharma industry classification

Industry
Product category
Long-acting injectable pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals

Keywords

  • Long-acting injectable pharmaceuticals
  • Generic drug development
  • Extended-release drug formulations
  • Active pharmaceutical ingredients
  • Aseptic fill-finish manufacturing

Where Mapi Pharma is headquartered

Location

Headquarters

HQ city
Ness Ziona
HQ country
Israel
HQ region
Middle East

Offices5 records

Markets served

Mapi Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

  1. Pharmaceutical Product Sales: Revenue from sale of proprietary pharmaceutical products including GA Depot and generic versions of marketed drugs like Fingolimod (Gilenya) and Apremilast (Otezla) in select regions.
  2. Licensing and Partnership Revenue: Revenue from strategic partnerships including manufacturing and supply agreements with Viatris for GA Depot commercialization globally, and product development agreements with partners like Zhejiang Jingxin for Chinese market.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Mapi Pharma product offering

Product offering

Core offering

Mapi Pharma develops proprietary long-acting depot injectables, complex active pharmaceutical ingredients, and pharmaceutical formulations for neurological, metabolic, oncology, and other chronic conditions. It also markets selected generic drugs and operates integrated GMP-approved API and finished-dosage-form manufacturing facilities.

Product overview

Mapi Pharma is a clinical-stage pharmaceutical company developing proprietary long-acting depot injectable drugs for lifecycle management of innovative and existing commercially successful pharmaceuticals. The company's lead product is GA Depot (Glatiramer Acetate Depot), a once-monthly injection for multiple sclerosis treatment partnered with Viatris and currently under FDA review. The pipeline includes multiple depot formulations across therapeutic areas: CNS disorders (Cariprazine Depot for schizophrenia, Pregabalin ER for neuropathic pain), metabolic diseases (Semaglutide Depot and Tirzepatide Depot for diabetes/weight management), and oncology (Anastrozole Depot for breast cancer). Mapi also markets generic versions of established drugs including Fingolimod (Gilenya), Apremilast (Otezla), and Naltrexone (Vivitrol). The company operates fully integrated R&D, clinical development, and GMP-approved manufacturing facilities in Israel.

Differentiator

Problem solved

Functional benefit

Products and services

  • GA Depot (Glatiramer Acetate Depot) A once-monthly 40 mg intramuscular glatiramer acetate injection for relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS), reducing administration from daily or thrice-weekly Copaxone schedules to once every four weeks.
  • Semaglutide Depot Long-acting injectable formulation of semaglutide for diabetes treatment, developed using Mapi's depot technology for once-monthly injection; currently in a Phase I/II study identified as ClinicalTrials.gov NCT07563699.
  • Tirzepatide Depot Long-acting injectable formulation of tirzepatide (Mounjaro/Zepbound) for chronic weight management, developed using Mapi's depot technology.
  • Anastrozole Depot Long-acting depot formulation of anastrozole (Arimidex) for adjuvant endocrine therapy to prevent recurrence in breast cancer, supported by Mapi intellectual property and pharmacokinetic modeling.
  • Cariprazine Depot Long-acting depot injectable for schizophrenia treatment, enrolling in a Phase I/II study with positive pharmacokinetic results supporting planned Phase III initiation in 2027.
  • Deutetrabenazine Depot Long-acting depot injectable for Huntington's disease.
  • Naltrexone Generic (Vivitrol) AB-rated generic version of naltrexone (Vivitrol) for opioid dependence treatment.
  • Fingolimod Generic (Gilenya) Generic version of fingolimod marketed under the Gilenya brand for multiple sclerosis treatment and sold in select regions.
  • Apremilast Generic (Otezla) Generic version of apremilast marketed as Apremil 30 mg for psoriasis treatment and sold in select regions.
  • Pregabalin ER Extended-release formulation of pregabalin (Lyrica) for the treatment of neuropathic pain and epilepsy.
  • Paliperidone Palmitate Long-acting depot injectable for the treatment of schizophrenia.
  • Buspirone ER Extended-release formulation of buspirone for the treatment of schizophrenia.
  • Tapentadol Pain-relief medication indicated for moderate-to-severe acute pain treatment, developed using Mapi's process for cost-effective production.

Quantifiable outcome

  • 30.1% reduction in annualized relapse rate (ARR) vs placebo in Phase III RMS study
  • +2 more outcomes

Companies that use Mapi Pharma

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles4 records

Mapi Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Mapi Pharma partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered minor, flagship and core.

  • Gaelan Medical Trade LLCminorChannel Partner/ Reseller/ Distributor · 21 October 2021Exclusive marketing and distribution agreement for Mapi products in UAE market.
  • Viatris (formerly Mylan)flagshipStrategic or Co-development Partner · 10 April 2018Mylan acquired global marketing rights to GA Depot in 2018; FDA accepted NDA filing with PDUFA target date of March 8, 2024; Mapi supplies product for commercial sale globally. Partnership strengthened with additional $20M investment in June 2020.
  • Zhejiang Jingxin Pharmaceutical Co.coreStrategic or Co-development Partner · 5 November 2016Chinese pharmaceutical company invested $10M initially in 2016 and $10M in 2018 for total $20M; product development agreement where Mapi develops products exclusively for Jingxin for Chinese market registration, manufacturing and marketing. Co-development of products for schizophrenia, diabetes, and other depot injectable indications.

Scale indicators9 records

Recent moves10 records

Expansion highlights7 records

Mapi Pharma competitors and assessment

Company assessment

Broad incumbents

  • Hikma Pharmaceuticals: Generic and specialty injectable pharma with a broad sterile injectable portfolio. Comparable on injectable manufacturing scale, complex generics expertise, and US/EU distribution reach relevant to Mapi's planned expansion.
  • Novartis: Markets Gilenya (fingolimod) for MS, a key competing oral therapy to injectable GA Depot. Comparable as a CNS specialty pharma incumbent whose franchise Mapi's pipeline and platform directly challenge.
  • Biogen: Major MS player (Tysabri, Avonex, Plegridy, Vumerity) and broader neuroscience biopharma. Comparable on CNS specialty pharma franchise development, large-scale MS clinical infrastructure, and neurology-focused commercial models.
  • Viatris: Global commercialization partner for GA Depot and a broader specialty/generic pharma with its own MS franchise (Copaxone authorized generic). Comparable as a large-scale neurology and complex injectable commercialization platform relevant to Mapi's go-to-market.
  • Roche: Markets Ocrevus, a leading high-efficacy MS therapy, and is expanding in progressive MS. Comparable as a broad incumbent whose MS franchise defines the competitive benchmark GA Depot must outperform in efficacy and adherence.
  • Amneal Pharmaceuticals: US-focused specialty and complex generic injectable manufacturer with an AffaMed and global footprint. Comparable on high-barrier generic injectables strategy and sterile manufacturing capabilities relevant to Mapi's generic and depot portfolio.

Direct peers

  • Tolmar Pharmaceuticals: Specialty pharma specializing in long-acting injectable depot technologies (e.g., Eligard for prostate cancer). Highly comparable on depot formulation know-how, sterile manufacturing, and urology/oncology injectable portfolio overlap.
  • Teva Pharmaceutical Industries: Originator of Copaxone (daily glatiramer acetate) for MS and a fellow Israeli specialty/generic pharma. Teva is the incumbent Mapi must displace in the GA franchise, and its authorized generic makes it the closest clinical and commercial comparable.
  • Heron Therapeutics: US specialty pharma built around long-acting injectable technology (Cinvanti, Sustol, Zynrelef). Closely comparable as a small-cap, depot/injectable-focused specialty pharma with similar capital and commercialization constraints.

Emerging players

  • Polpharma Biologics: European biosimilars and complex injectables developer with MS-relevant programs (e.g., natalizumab biosimilar). Comparable as an emerging specialty injectables player targeting the same prescribers and patient pool as Mapi's GA Depot.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Mapi Pharma social profiles

Digital presence

Mapi Pharma compliance and trust

Trust signal

Compliance3 records

Mapi Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mapi Pharma leadership team

Management profile

Number of profiles

Profiles2 records

Mapi Pharma funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mapi Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mapi Pharma

What does Mapi Pharma do?

Mapi Pharma develops proprietary long-acting depot injectables, complex active pharmaceutical ingredients, and pharmaceutical formulations for neurological, metabolic, oncology, and other chronic conditions. It also markets selected generic drugs and operates integrated GMP-approved API and finished-dosage-form manufacturing facilities.

Is Mapi Pharma a public or private company?

Mapi Pharma is a private company. It is classified as venture growth investor backed and is currently operating.

When was Mapi Pharma founded?

Mapi Pharma was founded in 2008. It employs 51 to 100 people.

Where is Mapi Pharma based?

Mapi Pharma is headquartered in Ness Ziona, Israel, in the Middle East region.

How does Mapi Pharma make money?

Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensing and Partnership Revenue.

Who are Mapi Pharma's main competitors?

Broad incumbents on record are Hikma Pharmaceuticals, Novartis, Biogen, Viatris, Roche and Amneal Pharmaceuticals. Direct peers are Tolmar Pharmaceuticals, Teva Pharmaceutical Industries and Heron Therapeutics. Polpharma Biologics is listed as an emerging player.

Does Mapi Pharma have an API?

No public API is recorded for Mapi Pharma.

What industry is Mapi Pharma in?

Mapi Pharma's product category is Long-acting injectable pharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Manila TimesMapi Pharma Announces Initial Phase I/IIa Clinical Results Supporting Continued Development of Once-Monthly Cariprazine DepotMapi Pharma announced initial Phase I/IIa clinical results for Cariprazine Depot, a once-monthly long-acting injectable formulation of the antipsychotic cariprazine. The trial data demonstrated that the treatment was safe and well-tolerated with no serious adverse events, supporting its continued development. Mapi plans to submit an Investigational New Drug application to the U.S. FDA by the end of 2026.BioSpaceMapi Pharma Announces Initial Phase I/IIa Clinical Results Supporting Continued Development of Once-Monthly Cariprazine DepotMapi Pharma announced initial Phase I/IIa results for its once-monthly Cariprazine Depot, showing a safety profile consistent with oral cariprazine, with no serious adverse events and mild injection site reactions. The company plans to submit an IND to the U.S. FDA by the end of 2026 with a partner expected to lead Phase 3 and marketing.BioSpaceMapi Pharma to Participate in the ASCO Annual Meeting and ADA 2026 Scientific SessionsMapi Pharma will participate in ASCO and ADA 2026 scientific sessions, seeking partnerships for long-acting depot formulations of semaglutide, tirzepatide, and anastrozole. The company is enrolling patients in a Phase I/II study for its semaglutide depot, with enrollment starting this month.GlobeNewswireMapi Pharma Explores U.S. Aseptic Manufacturing Facility to Support Growing Demand for Aseptic and Long-Acting Generic and innovative InjectablesMapi Pharma announced it is exploring a U.S.-based aseptic manufacturing facility to support its long-acting injectable pipeline, presenting the initiative at the SelectUSA Investment Summit in May 2026. The company will seek a partnership-based structure with strategic and financial investors. It also highlighted positive pharmacokinetic data for its Cariprazine Depot program, supporting a planned Phase III in 2027.GlobeNewswireMapi Pharma to Present Efficacy (EDSS) Data from Glatiramer Acetate Depot Long-Acting Injection Studies in Relapsing Forms of Multiple Sclerosis (RMS) and Primary Progressive Multiple Sclerosis (PPMS)Mapi Pharma will present EDSS efficacy data from GA Depot clinical studies in patients with relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) at the American Academy of Neurology Annual Meeting 2026 in Chicago. The Phase III RMS study (n=1,016) and Phase IIa PPMS study (n=30) showed EDSS stabilization, suggesting the long-acting injection may slow disability progression. GA Depot is currently in final regulatory review in Germany for the RMS indication with planned commercial launch in 2027 in Germany and broader EU markets in 2028, and the company is seeking a co-marketing partner for the EU.GlobeNewswireMapi Pharma to Host Virtual KOL Event to Discuss Glatiramer Acetate Once a Month Depot for Primary Progressive Multiple Sclerosis, on March 3, 2026Mapi Pharma will host a virtual KOL event on March 3, 2026, to discuss its Glatiramer Acetate Depot for primary progressive multiple sclerosis (PPMS) and relapsing forms. The company's Phase II PPMS results showed stable disability and a 96.6% disability progression-free rate, with the product in final review in Germany and a global Phase III study for PPMS.GlobeNewswireMapi Pharma to Present New Safety and Efficacy Data from Glatiramer Acetate Depot Long-Acting Injection Phase II Study in Patients with Primary Progressive Multiple Sclerosis (PPMS) at ACTRIMS Forum 2Mapi Pharma will present Phase II data for GA Depot in primary progressive multiple sclerosis at ACTRIMS Forum 2026. The open-label trial of 30 patients showed stable disability, with mean EDSS scores improving from 5.1 to 4.5 over three years and a 96.6% disability progression-free rate. The company plans a Phase III study in 2026 and commercial launch in relapsing MS in 2027.GlobeNewswireMapi Pharma is Seeking New Partnerships for Long-Acting Depot Drugs of Peptides for Self AdministrationMapi Pharma will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, Jan. 12-15, 2026, to seek new partnerships for its long-acting depot injectable products. The company has one partnered product, GA Depot for multiple sclerosis, and is developing an injectable cariprazine for schizophrenia. It is seeking to co-develop depot drugs with interested companies.GlobeNewswireMapi Pharma is Seeking New Partnerships for Long-Acting Depot Drugs of Peptides for Self AdministrationMapi Pharma Ltd., an Israeli late-stage biopharmaceutical company, announced it will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco from January 12-15, 2026, actively seeking new partnerships for its proprietary long-acting depot injectable products. The company's pipeline includes GA Depot for relapsing multiple sclerosis (partnered with Viatris, currently under FDA review), cariprazine for schizophrenia (enrolling in Phase I/II study), and other candidates including Deutetrabenazine Depot and Anastrazole Depot for various indications. Mapi operates an integrated R&D, clinical development, and GMP-approved manufacturing facility, positioning itself as a potential partner for companies seeking long-acting injectable lifecycle management products.YahooMapi Pharma is Seeking New Partnerships for Long-Acting Depot Drugs of Peptides for Self AdministrationMapi Pharma Ltd., an Israeli late-stage biopharmaceutical company, announced it will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco from January 12-15, 2026, where company management will seek new partnerships for its proprietary long-acting depot injectable products. The company's pipeline includes GA Depot for relapsing forms of multiple sclerosis (partnered with Viatris under FDA review), as well as candidates for Huntington's disease, breast cancer, diabetes, and schizophrenia. Mapi is looking to apply its depot technology to co-develop long-acting injectable lifecycle management products with other companies.